Theravance Biopharma Inc
Save
–
Market cap
–
Current P/E
6.90x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Similar securities
Based on sector and market capitalization
Report issue